There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Virpax Pharmaceuticals (VRPX – Research Report) and Kura Oncology (KURA – Research Report) with bullish sentiments.
Virpax Pharmaceuticals (VRPX)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Thursday at $0.77.
According to TipRanks.com, Rahman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Virpax Pharmaceuticals with a $4.00 average price target.
See today’s best-performing stocks on TipRanks >>
Kura Oncology (KURA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology today and set a price target of $32.00. The company’s shares closed last Thursday at $8.69, close to its 52-week low of $8.39.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kura Oncology with a $28.44 average price target, implying a 227.6% upside from current levels. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRPX:
